James Yue, MD
Orthopaedic Surgery · Shelton, CTNPI 1679557615
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $1,092,191 of the $1,324,087 with a category attached, or 82.5%. Aesculap AG accounts for 79.4% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2023 at $283,679 and has fallen 93.1% since, to $19,566 in 2025. Among orthopaedic surgery clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 562 payments — averaging $2356.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aesculap AG$1.1M
- Abbott$99K
- Aesculap Implant Systems, LLC$69K
- Globus Medical$26K
- Royal Biologics, Inc.$17K
- Intrinsic Therapeutics$10K
- plus $51K from 32 others
Across 112 payments — averaging $3874.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$324K
- Medtronic$58K
- Spineart USA Inc$14K
- Spineart SA$12K
- Nanofuse Biologics LLC$8K
- Globus Medical$7K
- plus $9K from 2 others
What the payments were for
- Royalty or licence$1,092,19182%
- Consulting fees$70,5145%
- Speaking & faculty fees$102,4728%
- Travel & lodging$47,3774%
- Food & beverage$11,5111%
- Gifts$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aesculap AG | 26 | $1,051,480 |
| Abbott | 225 | $99,342 |
| Aesculap Implant Systems, LLC | 66 | $68,880 |
| Globus Medical(2 entities) | 61 | $25,804 |
| Royal Biologics, Inc. | 27 | $17,085 |
| Intrinsic Therapeutics | 13 | $10,400 |
| Saluda Medical Americas, Inc. | 6 | $8,986 |
| B. Braun Medical Inc. | 8 | $8,066 |
| Aesculap, Inc. | 2 | $8,021 |
| Innovasis Inc | 12 | $8,012 |
| Elliquence, LLC | 2 | $6,643 |
| Arthrex | 9 | $3,504 |
| Medtronic(2 entities) | 26 | $2,079 |
| Zimmer Biomet | 9 | $1,145 |
| Alphatec Spine, Inc | 1 | $875 |
| Polaris Technology Solutions LLC | 4 | $847 |
| Ossdsign USA Incorporated | 3 | $715 |
| Vy Spine LLC | 2 | $235 |
| Amgen | 24 | $225 |
| Johnson & Johnson | 7 | $221 |
| Boston Scientific | 2 | $159 |
| Icotec Medical Inc. | 2 | $154 |
| 4web, Inc. | 1 | $150 |
| 7d Surgical Inc. | 2 | $127 |
| Vertiflex, Inc. | 3 | $116 |
| Arteriocyte Medical Systems, Inc. | 2 | $101 |
| Cerapedics Inc. | 2 | $97 |
| Centinel Spine, LLC | 2 | $92 |
| VB Spine LLC | 1 | $83 |
| Providence Medical Technology, Inc. | 2 | $81 |
| Si-bone, Inc. | 1 | $72 |
| Spinal Simplicity, LLC | 2 | $63 |
| Nalu Medical, Inc. | 1 | $55 |
| Richard Wolf Medical Instruments Corp. | 2 | $48 |
| Augmedics Inc. | 1 | $46 |
| Surgalign Spine Technologies, Inc. | 1 | $37 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Vertex | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVL$809,730
- ACTIVL ARTIFICIAL DISC$317,074
- PROCLAIM$92,996
- Fibrinet$20,881
- BARRICAID ACD (ANNULAR CLOSURE DEVICE)$10,000
- Evoke SCS$8,906
- RISE Intra LIF$8,423
- CONTIPLEX ANESTHESIA CATHETERS$7,941
- CREO MCS$6,766
- RISE$6,500
- Barricaid Annular Closure Device$3,600
- Precision TLIF$1,625
- Proclaim IPG$1,513
- MazorX - Renaissance$1,435
- Neuromodulation Dspsbls and Accs$1,400
- RISE-L$1,300
- OsseoFix$875
- Mobi-C$764
- AESCULAP$625
- Fibricell$500
How this compares
$1,324,087 in reported general payments places this provider in the 95th percentile of 273 orthopaedic surgery providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 32 | $828 |
| Gabapentin | 59 | $589 |
| Lidocaine | 12 | $531 |
| Tramadol Hcl | 123 | $456 |
| Cyclobenzaprine Hcl | 54 | $328 |
| Celecoxib | 31 | $312 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $183 |
| Oxycodone Hcl | 32 | $153 |
| Meloxicam | 12 | $88 |
| Diazepam | 17 | $26 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Shelton
- Peter WhangNew Haven$1.8M
- Paul SethiGreenwich$1.5M
- Robert DeveneyDanbury$907K
- James PaceFarmington$721K
- Isaac MossFarmington$676K
- David FrumbergNew Haven$288K
- John KeggiMiddlebury$264K
- Lauren GeaneyFarmington$263K
- Robert StantonFairfield$199K
- Cory EdgarFarmington$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.